Since epigenetic modifications are reversible and DNA demethylating drugs such as 5-azacytidine and 5-aza-2-deoxycytidine (decitabine) are approved for the clinical treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia,58 our results also suggest that targeting epigenetic GPX4 suppression and ferroptosis through DNMT intervention could be a feasible and effective strategy for treating patients with OP and related bone diseases. Here, GPX4 is linked to chronic myelomonocytic leukemia.